PHOENIX: A randomized controlled trial o
โ
Natalie Bzowej; David R. Nelson; Norah A. Terrault; Gregory T. Everson; Lichen L
๐
Article
๐
2011
๐
John Wiley and Sons
๐
English
โ 249 KB
๐ 2 views
The efficacy, tolerability, and safety of the prophylactic treatment of hepatitis C virus (HCV) after liver transplantation (LT) with peginterferon alfa-2a and ribavirin are not known. LT recipients with HCV were randomized to peginterferon alfa-2a/ribavirin treatment or observation 10 to 26 weeks p